The role of GLP-2 on pISC during the adaptive response following intestinal resection is not defined. The GLP-2 receptor (GLP-2R) is predominantly expressed by enteroendocrine cells (37), enteric neurons (1,26), and subepithelial myofibroblasts (27) throughout the GI tract, with highest expression in the jejunum (25). intestinal caliber. Acebilustat GLP-2 increased proliferation and intestinal morphometrics in all groups. This study shows that, in mice, GLP-2 promotes jejunal pISC growth only in the period immediately following ICR. This is associated with increased IGF-I and accelerated adaptive increases in mucosal mass. These data provide clinical rationale relevant to the optimal timing of GLP-2 in patients with intestinal failure. Keywords:intestinal adaptation glucagon-like peptide-2(GLP-2) is usually a 33-amino acid peptide secreted by intestinal L cells in the ileum and colon, which influences multiple aspects of intestinal homeostasis (9). In normal physiological says, GLP-2 inhibits gastrointestinal (GI) motility and gastric acid secretion, stimulates nutrient absorption, and reduces intestinal epithelial permeability (8). In adult total parenteral nutrition (TPN)-fed pigs, administration of GLP-2 increased intestinal blood flow (13) and decreased apoptosis (3,30), yet, in a neonatal piglet model of short bowel syndrome, GLP-2 did not result in clinical improvement (28). This is in contrast to numerous rodent experiments where GLP-2 has been shown to augment the adaptive response following small bowel resection by increasing villus height, crypt depth, proliferation, and decreasing apoptosis (20,24,32). In humans as well as rodents, early morphological effects are observed with GLP-2 treatment, but these effects are not sustained following discontinuation of therapy (16). Clinical findings in humans after bowel resection typically demonstrate increased intestinal caliber without changes in crypt/villus morphology (38). Following significant intestinal loss, TPN is usually often required to support both nutrition and fluid requirements. Although many of these patients are able to fully transition off TPN over the first one to two years following intestinal loss, limited treatment options are available to improve adaptive growth in those patients who remain dependent on TPN. Because of the potent mitogenic Acebilustat effects of GLP-2, there is considerable desire for its potential as a therapy for patients with chronic intestinal failure. Initial clinical studies evaluating Teduglutide, a GLP-2 analog resistant to degradation by dipeptidyl peptidase IV, have exhibited improved intestinal wet excess weight and absorption in short bowel patients (18). To date, this represents the only hormonally induced adaptive intestinal growth (as evaluated by intestinal biopsies) in patients with chronic intestinal failure. Regrettably, the effects of GLP-2 have not been clinically dramatic or sustained following discontinuation of the peptide (16). The limited clinical efficacy of GLP-2 may be due to the timing of GLP-2 therapy because most patients receive the growth factor Acebilustat many years after developing intestinal failure when humoral factors are less effective (16,17). Recent studies in our laboratory provided evidence that growth of intestinal progenitors and putative stem cells (pISC) occurs early following ileo-cecal resection (ICR) (6). Resection-induced pISC growth precedes increases CD350 in crypt fission and the production of new crypts, leading to sustained increases in the caliber of the remnant intestine (6). In Acebilustat our ICR model, sustained increases in intestinal caliber are not accompanied by managed increases in proliferation, crypt depth, or villus height. This suggests that early pISC growth, rather than maintained proliferation, is integral for adaptation following intestinal loss (6). The role of GLP-2 on pISC during the adaptive response following intestinal resection is not defined. The GLP-2 receptor (GLP-2R) is usually predominantly expressed by enteroendocrine cells (37),.